183622-35-7 Usage
Uses
Used in Pharmaceutical Industry:
2-Nitro-5-piperazin-1-yl-benzoic acid is used as an intermediate in the synthesis of potential drug candidates for its anti-cancer and anti-inflammatory properties. It is being researched for its potential use in the treatment of various diseases, offering a promising avenue for therapeutic development.
Used in Anticancer Applications:
In the field of oncology, 2-Nitro-5-piperazin-1-yl-benzoic acid is employed for its anti-cancer properties, targeting the synthesis and activity of various cancer cells. Its potential role in cancer treatment is currently under investigation, with the aim of identifying its specific mechanisms of action and therapeutic efficacy.
Used in Anti-inflammatory Applications:
2-NITRO-5-PIPERAZIN-1-YL-BENZOIC ACID also serves as an anti-inflammatory agent, making it a candidate for the development of treatments targeting inflammation-related conditions. Its precise role in modulating inflammatory responses is an area of ongoing research.
Used in Antimicrobial and Antifungal Applications:
Beyond its pharmaceutical applications, 2-Nitro-5-piperazin-1-yl-benzoic acid has demonstrated antimicrobial and antifungal activities. This makes it a candidate for use in various industries, including medicine, where it could be employed in the development of new antimicrobial and antifungal agents to combat resistant strains and infections.
Check Digit Verification of cas no
The CAS Registry Mumber 183622-35-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,3,6,2 and 2 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 183622-35:
(8*1)+(7*8)+(6*3)+(5*6)+(4*2)+(3*2)+(2*3)+(1*5)=137
137 % 10 = 7
So 183622-35-7 is a valid CAS Registry Number.
183622-35-7Relevant articles and documents
BICYCLIC QUINAZOLINONE DERIVATIVES
-
Page/Page column 53-54, (2016/10/31)
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R12, R13, R14, A1, A2, A3, n and m are as described herein.
TRIAZOLO [1, 5-A] QUINOLINES AS ADENOSINE A3 RECEPTOR LIGANDS
-
Page/Page column 40-41, (2009/01/24)
The present invention relates to the adenosine A3 receptor ligands of the general formula (I), within them favourably to the antagonists, to their salts, solvates, N-oxides and isomers, to the pharmaceutical compositions containing the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the use of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the preparation of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, as well as to the new intermediates of the general formula (II), (VI), (XI), (XII) and (XV), and to the preparation thereof.
Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1(1H)-isoquinolinone-based antagonists and ethyl ester prodrugs
Hutchinson, John H.,Cook, Jacquelynn J.,Brashear, Karen M.,Breslin, Michael J.,Glass, Joan D.,Gould, Robert J.,Halczenko, Wasyl,Holahan, Marie A.,Lynch, Robert J.,Sitko, Gary R.,Stranieri, Maria T.,Hartman, George D.
, p. 4583 - 4591 (2007/10/03)
The structure-activity relationship of a series of orally active glycoprotein IIb/IIIa antagonists containing a nitrogen heterocycle grafted onto a 3,4-dihydro-1(1H)-isoquinolinone core is described. These compounds are structurally novel analogs of the p
